Invention Grant
- Patent Title: Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds
-
Application No.: US16633371Application Date: 2018-08-28
-
Publication No.: US11365185B2Publication Date: 2022-06-21
- Inventor: Tianwei Ma , Liang Wu , Xuejun Zhang
- Applicant: Eli Lilly and Company
- Applicant Address: US IN Indianapolis
- Assignee: Eli Lilly and Company
- Current Assignee: Eli Lilly and Company
- Current Assignee Address: US IN Indianapolis
- Agent Thomas P. Weber
- Priority: WOPCT/CN2017/100354 20170904
- International Application: PCT/US2018/048249 WO 20180828
- International Announcement: WO2019/046239 WO 20190307
- Main IPC: C07D401/14
- IPC: C07D401/14 ; A61P1/16 ; C07D403/12 ; C07D403/14
Abstract:
The present invention provides a compound of formula (I) or a pharmaceutical salt thereof, use, methods for its preparation are described.
Public/Granted literature
- US20200231568A1 LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS Public/Granted day:2020-07-23
Information query
